0
0
0
0
1
2
3
$0
Is Boston Scientific solid or fragile? The Finex Financial Health Scanner reads BSX's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $20.1B |
|---|---|
| Net income | $2.9B |
| Operating margin | 18.0% |
| Net margin | 14.4% |
| Cash and investments | $2.0B |
| Total debt | $11.4B |
| Free cash flow | $2.5B |
| Revenue growth (1 year) | 19.9% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.